MCID: ISC004
MIFTS: 60

Ischemia

Categories: Blood diseases, Cardiovascular diseases, Metabolic diseases

Aliases & Classifications for Ischemia

MalaCards integrated aliases for Ischemia:

Name: Ischemia 12 54 43 15 17 71
Acute Coronary Syndrome 71

Classifications:



External Ids:

Disease Ontology 12 DOID:326
MeSH 43 D007511
NCIt 49 C34738
SNOMED-CT 67 52674009
UMLS 71 C0022116 C0948089

Summaries for Ischemia

Disease Ontology : 12 A vascular disease that is characterized by a restriction in blood supply to tissues.

MalaCards based summary : Ischemia, also known as acute coronary syndrome, is related to limb ischemia and retinal ischemia, and has symptoms including muscle weakness, polydipsia and angina pectoris. An important gene associated with Ischemia is ENSG00000278514 (), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Development Angiotensin activation of ERK. The drugs Diphenhydramine and Zolpidem have been mentioned in the context of this disorder. Affiliated tissues include heart, brain and liver, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Wikipedia : 74 Ischemia or ischaemia is a restriction in blood supply to tissues, causing a shortage of oxygen that is... more...

Related Diseases for Ischemia

Diseases related to Ischemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1536)
# Related Disease Score Top Affiliating Genes
1 limb ischemia 35.2 VEGFA NOS3 CXCL12 ACE
2 retinal ischemia 35.1 VEGFA CXCL12 CASP3
3 coronary artery anomaly 33.8 VEGFA PON1 NOS3 GJA1 CASP3 ACE
4 vascular disease 33.7 VEGFA PON1 NOS3 HMOX1 EPO CXCL12
5 nonarteritic anterior ischemic optic neuropathy 33.3 VEGFA NOS3 ACE
6 cerebral hypoxia 33.3 CASP9 CASP3
7 ischemic colitis 33.2 VEGFA HMOX1 ACE
8 microvascular complications of diabetes 5 33.2 VEGFA SOD2 PON1 NOS3 CXCL12 ACE
9 exudative vitreoretinopathy 1 33.2 VEGFA NOS3 EPO CASP3
10 myocardial infarction 33.1 VEGFA PON1 NOS3 HMOX1 GJA1 EPO
11 peripheral vascular disease 32.3 VEGFA NOS3 EPO ACE
12 coronary stenosis 32.1 PON1 CXCL12 ACE
13 peripheral artery disease 32.1 VEGFA NOS3 HMOX1 ACE
14 testicular torsion 31.9 NOS3 CASP3 ACE
15 pulmonary edema 31.8 NOS3 HMOX1 EPO ACE
16 arteriosclerosis 31.8 PON1 NOS3 HMOX1 CXCL12 ACE
17 kidney disease 31.8 VEGFA PON1 NOS3 HMOX1 EPO ACE
18 congestive heart failure 31.8 VEGFA NOS3 EPO ACE
19 atherosclerosis susceptibility 31.7 VEGFA PON1 NOS3 ACE
20 chronic kidney disease 31.7 VEGFA PON1 NOS3 HMOX1 EPO ACE
21 carotid stenosis 31.7 VEGFA NOS3 ACE
22 vascular dementia 31.6 VEGFA PON1 CASP3 ACE
23 pre-eclampsia 31.6 VEGFA PON1 NOS3 HMOX1 ACE
24 stroke, ischemic 31.6 SOD2 PON1 NOS3 GJA1 CXCL12 CASP9
25 retinal vascular disease 31.6 VEGFA NOS3 CASP3 ACE
26 heart disease 31.6 VEGFA SOD2 PON1 NOS3 HMOX1 GJA1
27 retinal artery occlusion 31.4 VEGFA HMOX1 ACE
28 sleep apnea 31.4 VEGFA NOS3 EPO ACE
29 retinal vein occlusion 31.4 VEGFA CXCL12 ACE
30 pheochromocytoma 31.4 VEGFA EPO EGR1 CASP3 ACE
31 diabetic neuropathy 31.4 VEGFA SOD2 PON1 EPO ACE
32 neuroblastoma 31.3 VEGFA SOD2 REST HMOX1 EGR1 CXCL12
33 hypertension, essential 31.3 VEGFA SOD2 PON1 NOS3 HMOX1 GJA1
34 diabetes mellitus 31.3 VEGFA SOD2 PON1 NOS3 HMOX1 EPO
35 renovascular hypertension 31.2 NOS3 HMOX1 ACE
36 eclampsia 31.2 VEGFA NOS3 ACE
37 deficiency anemia 31.2 PON1 HMOX1 EPO CXCL12 ACE
38 diabetic macular edema 31.2 VEGFA SOD2 NOS3 EPO
39 dilated cardiomyopathy 31.1 VEGFA SOD2 NOS3 HMOX1 GJA1 CASP9
40 alzheimer disease 31.0 VEGFA SOD2 REST PON1 NOS3 MAP3K5
41 intracranial aneurysm 31.0 NOS3 CASP3 ACE
42 sickle cell anemia 30.9 NOS3 HMOX1 EPO
43 portal hypertension 30.9 VEGFA NOS3 ACE
44 hydrocephalus 30.9 VEGFA EPO CASP3 ACE
45 uremia 30.9 PON1 EPO ACE
46 diabetic polyneuropathy 30.8 VEGFA SOD2 NOS3
47 body mass index quantitative trait locus 11 30.8 VEGFA SOD2 PRKAA2 PON1 NOS3 HMOX1
48 diabetes mellitus, noninsulin-dependent 30.8 VEGFA PRKAA2 PON1 NOS3 HMOX1 CASP3
49 acute chest syndrome 30.8 VEGFA NOS3 HMOX1
50 renal hypertension 30.8 NOS3 EPO ACE

Graphical network of the top 20 diseases related to Ischemia:



Diseases related to Ischemia

Symptoms & Phenotypes for Ischemia

UMLS symptoms related to Ischemia:


muscle weakness, polydipsia, angina pectoris, anoxemia

GenomeRNAi Phenotypes related to Ischemia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 ACE CASP3 CASP9 HMOX1 MAP3K5 NOL3
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 ACE CASP3 CASP9 HMOX1 MAP3K5 NOL3

MGI Mouse Phenotypes related to Ischemia:

45 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.43 ACE ADORA3 CASP3 CASP9 CXCL12 EGR1
2 cellular MP:0005384 10.41 CASP3 CASP9 CXCL12 EGR1 EPO GJA1
3 homeostasis/metabolism MP:0005376 10.33 ACE ADORA3 CASP3 EGR1 EPO GJA1
4 behavior/neurological MP:0005386 10.31 ACE ADORA3 CASP3 EGR1 GJA1 HMOX1
5 hematopoietic system MP:0005397 10.29 ACE ADORA3 CASP3 CASP9 CXCL12 EGR1
6 immune system MP:0005387 10.25 ACE ADORA3 CASP3 CASP9 CXCL12 EGR1
7 mortality/aging MP:0010768 10.18 ACE CASP3 CASP9 CXCL12 EGR1 EPO
8 endocrine/exocrine gland MP:0005379 10.15 ACE CASP3 CASP9 EGR1 GJA1 HMOX1
9 muscle MP:0005369 10.02 CASP3 CXCL12 EPO GJA1 HMOX1 NOL3
10 liver/biliary system MP:0005370 10.01 ACE CXCL12 EGR1 EPO HMOX1 NOS3
11 nervous system MP:0003631 10 CASP3 CASP9 CXCL12 EGR1 GJA1 HYOU1
12 renal/urinary system MP:0005367 9.76 ACE ADORA3 CASP3 HMOX1 NOS3 PRKAA2
13 reproductive system MP:0005389 9.65 ACE CASP3 CXCL12 EGR1 GJA1 HMOX1
14 respiratory system MP:0005388 9.32 ADORA3 CASP3 CASP9 EGR1 EPO GJA1

Drugs & Therapeutics for Ischemia

Drugs for Ischemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1020)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
2
Zolpidem Approved Phase 4 82626-48-0 5732
3
Promethazine Approved, Investigational Phase 4 60-87-7 4927
4
Fenoldopam Approved Phase 4 67227-56-9, 67227-57-0 3341
5
Saxagliptin Approved Phase 4 361442-04-8 11243969
6
Capsaicin Approved Phase 4 404-86-4 1548943
7
Gliclazide Approved Phase 4 21187-98-4 3475
8
Udenafil Approved, Investigational Phase 4 268203-93-6 6918523
9
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
10
Nadroparin Approved, Investigational Phase 4
11
Streptokinase Approved, Investigational Phase 4 9002-01-1
12
Adenosine Approved, Investigational Phase 4 58-61-7 60961
13
Ticlopidine Approved Phase 4 55142-85-3 5472
14
Pravastatin Approved Phase 4 81093-37-0 54687
15
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
16
Bezafibrate Approved, Investigational Phase 4 41859-67-0 39042
17
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
18
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
19
Famotidine Approved Phase 4 76824-35-6 3325
20
Salicylic acid Approved, Investigational, Vet_approved Phase 4 69-72-7 338
21
Lornoxicam Approved, Investigational Phase 4 70374-39-9 5282204
22
Simvastatin Approved Phase 4 79902-63-9 54454
23
Fondaparinux Approved, Investigational Phase 4 104993-28-4
24
Paclitaxel Approved, Vet_approved Phase 4 33069-62-4 36314
25
Pantoprazole Approved Phase 4 102625-70-7 4679
26
Abciximab Approved Phase 4 143653-53-6
27
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
28
Regadenoson Approved, Investigational Phase 4 313348-27-5 219024
29
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
30
Eszopiclone Approved, Investigational Phase 4 138729-47-2 969472
31
Acetylcarnitine Approved, Investigational Phase 4 3040-38-8 7045767
32
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
33
Argatroban Approved, Investigational Phase 4 74863-84-6 152951
34
Methylnaltrexone Approved Phase 4 916055-93-1, 83387-25-1 6603824
35
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
36
Insulin lispro Approved Phase 4 133107-64-9
37
Sodium citrate Approved, Investigational Phase 4 68-04-2
38 Hydrotalcite Approved, Experimental, Investigational Phase 4 12304-65-3
39
Aluminum hydroxide Approved, Investigational Phase 4 21645-51-2
40
Magnesium hydroxide Approved, Investigational Phase 4 1309-42-8
41
Sucralfate Approved Phase 4 54182-58-0
42
Iloprost Approved, Investigational Phase 4 78919-13-8 6443959
43
Eplerenone Approved Phase 4 107724-20-9 150310 443872
44
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
45
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
46
Digoxin Approved Phase 4 20830-75-5 30322 2724385
47
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
48
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
49 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
50
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0

Interventional clinical trials:

(show top 50) (show all 7533)
# Name Status NCT ID Phase Drugs
1 Phase IV: A Comparison of Reduced-dose Prasugrel and Clopidogrel in Elderly Patients With Acute Coronary Syndrome Undergoing Early Percutaneous Coronary Intervention (PCI) Unknown status NCT01777503 Phase 4 prasugrel;Clopidogrel
2 Telmisartan vs Ramipril for Reduction of Inflammation and Recruitment of Endothelial Progenitor Cells After Acute Coronary Syndrome Unknown status NCT00702936 Phase 4 TELMISARTAN;RAMIPRIL
3 Acute Rosuvastatin for Preventing Myocardial Damage in Patients With Acute Coronary Syndrome Unknown status NCT01245803 Phase 4 additional rosuvastatin loading;placebo control
4 Clopidogrel Reloading in Patients With Non-ST Elevation Acute Coronary Syndrome Undergoing PCI on Chronic Clopidogrel Therapy. Results of the ARMYDA RELOAD ACS (Antiplatelet Therapy for Reduction of MYocardial Damage During Angioplasty in Acute Coronary Syndrome) Randomized Trial. Unknown status NCT01572129 Phase 4 Clopidogrel;Placebo
5 Safety and Efficacy of the Novel Selective Nicotinic Receptor Partial Agonist, CHANTIX (Varenicline) in Patients With Acute Coronary Syndrome Unknown status NCT01170338 Phase 4 Varenicline 100 mg by mouth twice daily;control
6 Chewing Ticagrelor Versus Prasugrel in ST-elevation Myocardial Infarction - A Platelet Reactivity Study Unknown status NCT03016611 Phase 4 Chewing Ticagrelor LD;Chewing Prasugrel LD
7 Colchicine for Acute Coronary Syndromes. A Multicenter Double Blind Randomized Trial. Unknown status NCT01906749 Phase 4 Colchicine;Placebo
8 Efficacy and Safety of New Generation Drug Eluting Stents Associated With an Ultra Short Duration of Dual Antiplatelet Therapy. Design of the Short Duration of Dual antiplatElet Therapy With SyNergy II Stent in Patients Older Than 75 Years Undergoing Percutaneous Coronary Revascularization. Unknown status NCT02099617 Phase 4
9 evAluation of Glycemic RangE During acutE Coronary syndroME in Nondiabetic paTients Unknown status NCT02932592 Phase 4
10 Intracoronary Cocktail Injection Improves Outcomes of Fractional Flow Reserve Guided Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrom (ACS) Unknown status NCT02592720 Phase 4 cocktail
11 Multicenter Trial on Clinical Utility of Acarbose in Patients With Ischemic Heart Disease Accompanied by Abnormal Glucose Regulation Unknown status NCT00858676 Phase 4 acarbose
12 A comParison on Platelet Resistance With Ticagrelor or Standard-Dose Clopidogrel Study Among SeVerE Chronic Kidney Disease/ End-Stage-Renal-Disease Patients With Recent Acute Coronary Syndrome. Unknown status NCT02459288 Phase 4 Clopidogrel first;Ticagrelor first
13 Effectiveness and Tolerability of Early Initiation of Combined Lipid -Lowering Therapy Included Simvastatin and Fenofibrate vs Simvastatin Alone in Patients With Type 2 Diabetes Mellitus, Hypertriglyceridemia and Acute Coronary Syndrome Unknown status NCT02015988 Phase 4 Fenofibrate;Simvastatin
14 Effects of Selective and Nonselective Beta-blockade on Platelet Aggregation in Patients With Acute Coronary Syndrome Unknown status NCT02809820 Phase 4 Carvedilol;Metoprolol
15 A Randomized Comparison of Low-dose Versus High-dose Rosuvastatin on Optical Coherence Tomography Based Early Vascular Healing for Patients With Acute Coronary Syndrome Unknown status NCT03007524 Phase 4 High dose Rosuvastatin;Low dose Rosuvastatin
16 A Prospective, Multi-center, Randomized, Controlled Study to Evaluate the Effect of DiPeptidyl-Peptidase 4 Inhibitor on Vascular Healing After Biodegradable Polymer Based Sirolimus Eluting Stent Implantation in Diabetic Patients: OCT Study (DIAMOND-OCT) Unknown status NCT02802644 Phase 4 Sitagliptin;Non DPP-4 Inhibitor
17 The Prediction of Extent and Risk Profile of Coronary Atherosclerosis (Examined by Intravascular Ultrasound, Virtual Histology and Optical Coherence Tomography) and Their Changes During Lipid-lowering Therapy Based on Non-invasive Techniques. Unknown status NCT01773512 Phase 4 Rosuvastatin
18 Intensive Lipid Lowering Treatment in Patients With Non-ST-elevation ACS Undergoing Percutaneous Coronary Intervention Unknown status NCT01040936 Phase 4 Atorvastatin;Atorvastatin
19 SWITCH 600/60: The Effect of Reloading Prasugrel in a Patient Who Has Already Received a Loading Dose (LD) of Clopidogrel Unknown status NCT01365221 Phase 4 Prasugrel;Prasugrel
20 Assessment of the Effects of Ezetimibe on Coronary Plaque Volume in Patients With Acute Coronary Syndrome Unknown status NCT01068093 Phase 4 Ezetimibe
21 Comparison of Platelet Reactivity in Patients With Acute Coronary Syndrome Given Patent Clopidogrel Versus Generic Clopidogrel: Randomized Controlled Trial Unknown status NCT02628587 Phase 4 Generic clopidogrel;Patent clopidogrel
22 Effects of Zolpidem CR in Sleep and Clinical Outcomes of Patients in Cardiac Intensive Care Unit Unknown status NCT01920334 Phase 4 Zolpidem CR 12.5mg;Placebo
23 The Effect of Tongguan Capsule for MicroRNA Profiles Between Qi-Stagnation and Qi-Deficiency in Coronary Heart Disease Patients With Blood Stasis Syndrome Undergoing Percutaneous Coronary Intervention Unknown status NCT02850627 Phase 4 Tongguan capsule;placebo capsule
24 The Safety and Efficacy of Intensive Statin Therapy in PCI Patient With Acute Coronary Syndrome Unknown status NCT01372839 Phase 4 Atorvastatin;Statin
25 A Prospective, Multicenter, Randomized, Open-label Trial to Evaluate Efficacy and Safety of 5mg Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome Who Underwent Percutaneous Coronary Intervention With BiomatrixTM Stent Unknown status NCT02446730 Phase 4 Prasugel;Clopidogrel
26 Assessment of Coronary Flow Reserve by Doppler Flow WIre in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Differences Between the Loading Dose of Prasugrel and Ticagrelor . Unknown status NCT02032303 Phase 4 Ticagrelor loading;Prasugrel loading
27 Randomised, Double-blind, Placebo-controlled Trial of IVabradine in Patients With Acute Coronary Syndrome: Effects of the If Current Inhibitor Ivabradine or rEduction of Inflammation maRkers in Patients With Acute Coronary Syndrome Unknown status NCT00815100 Phase 4 Ivabradine;Placebo
28 An Open-label Study Evaluating the Acute Efficacy of Treatment With Ticagrelor Versus Clopidogrel on Myocardial Tissue-level Perfusion Assessed by TMPFC and MRI in Patients With High-risk NSTE-ACS Undergoing Early PCI(EARLY-MYO II) Unknown status NCT02201667 Phase 4 Ticagrelor;clopidogrel;Aspirin
29 A 30-day, Randomized, Open-Label, Multicenter Study Exploring Efficacy of Intensive Rosuvastatin Treatment Peri-PCI in Chinese Patients With NSTE-ACS Unknown status NCT02284503 Phase 4 Rosuvastatin
30 Efficacy and Safety of the YUKON Drug Eluting Stent in Diffuse Coronary Artery Disease Unknown status NCT01418794 Phase 4
31 Intervention Study Measuring Inflammatory Cytokine Levels in the Serum of Patients Who Underwent an Acute MI, and the Influence of Vitamin D on These Levels Unknown status NCT01115842 Phase 4 Vitamin D
32 Assessment of Coronary Flow Reserve by Doppler Flow Wire in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Differences Between the Loading Dose of Ticagrelor and Clopidogrel Unknown status NCT02032290 Phase 4 ticagrelor loading;Clopidogrel loading
33 Fenoldopam for Prevention of Acute kidNey Injury in Patients With aCute coronarY Syndrome Undergoing Coronary Angiography and/or Percutaneous Coronary Intervention - The FANCY Trial Unknown status NCT01690832 Phase 4 standard saline infusion;fenoldopam infusion
34 Different Doses Rosuvastatin Effect on Telomere-telomerase System in Acute Coronary Syndrome Patients After Percutaneous Coronary INtervention: RETAIN Study Unknown status NCT02299245 Phase 4 rosuvastatin
35 Comparison of the Effects of Ticagrelor Versus Clopidogrel on Endothelial Dysfunction and Vascular Inflammation in Patients With Prior Non-ST-segment Acute Coronary Syndrome Unknown status NCT02379676 Phase 4 Ticagrelor;Clopidogrel
36 A Randomized Prospective Multicenter Trial to Examine Vascular Healing at 1 and 6 Month(s) After Deployment of TItanium-nitride-oxide-coated OPTIMAX™ Bio-active-stent (BAS) Stent and SYNERGY™ Everolimus-Eluting Stent (EES) in Patients With Acute Coronary Syndromes by Means of Optical Coherence Tomography Unknown status NCT02464397 Phase 4
37 Nanjing First Hospital, Nanjing Medical University Unknown status NCT01171911 Phase 4 Nicardipine , Esmolol
38 Effects of the Administration Of Antithrombin on the Coagulation Status and on the Inflammatory Response in Patients With Low Plasmatic Levels of Antithrombin After Cardiac Surgery Unknown status NCT01201070 Phase 4 antithrombin III
39 A Double-Blind, Placebo-Controlled Study of Escitalopram in the Prevention of Depression in Patients With Acute Coronary Syndrome Unknown status NCT00140257 Phase 4 Escitalopram
40 OCT Evaluation of Stent Struts Re-endothelization in Patients With Acute Coronary Syndromes: a Comparison of the Intrepide™ Stent vs. Taxus™ Unknown status NCT00914420 Phase 4
41 Optimizing Timing of Coronary Artery Bypass Surgery in Patients Presenting With Acute Coronary Syndrome and Treated With Second Generation ADP Receptor Antagonist Unknown status NCT02627521 Phase 4 Ticagrelor
42 COmparison of the Pharmacodynamics and Pharmacokinetics of Ticagrelor Versus Clopidogrel in Patients With Chronic Kidney Disease and Non-ST-Elevation Acute Coronary Syndromes(OPT-CKD Trial) Unknown status NCT02578537 Phase 4 Ticagrelor;Clopidogrel
43 A 12-Week, Randomized, Open-Label, Multicenter Study Exploring Low-Density Lipoprotein Cholesterol Lowering Efficacy and Safety of Rosuvastatin 20 mg/Day Compared to10 mg/Day in Chinese Patients With Acute Coronary Syndromes Unknown status NCT02077257 Phase 4 Rosuvastatin
44 Ticagrelor Versus Clopidogrel in Myocardial Salvage in Patients With ST-elevation Myocardial Infarction (STEMI) Undergoing Primary Percutaneous Coronary Intervention: A Magnetic Resonance Imaging Study (TIGER Study) Unknown status NCT02792712 Phase 4 Ticagrelor;Clopidogrel
45 The Study to Assess the Effect of Trimetazidine on Index of Microcirculatory Resistance (IMR), Measured by Coronary Pressure and Temperature Wire, in Patients With Stable Coronary Artery Disease Unknown status NCT02107144 Phase 4 trimetazidine
46 Epicardial Fat Evaluation to Predict Clinical Outcomes in Patients Affected by Coronary Artery Disease and Treated by Coronary Artery Bypass Grafting: Diabetic vs. Non Diabetic Patients, and Incretin Therapy Effect; The EPI.FAT.IN Study Unknown status NCT03360981 Phase 4 Incretins
47 Effect of Rosuvastatin Therapy on HDL2 Level and Antiatherosclerotic Reverse Cholesterol Transport Process in Chinses CAD Patients With Hyperlipidemia Unknown status NCT02593487 Phase 4 Rosuvastatin 10mg/d group;Rosuvastatin 20mg/d group
48 A French, Multicentric, Randomized, Simple Blind, Superiority Study Comparing the Efficiency and the Safety at 24 Months of the Stent Titan2 Versus Bare Metal Stent in Cobalt-Chrome in All Comers Patients Among Which 40 % Present an ACS. Unknown status NCT01918150 Phase 4
49 Customized Choice of P2Y12 Oral Receptor Blocker Based on Phenotype Assessment Via Point of Care Testing Unknown status NCT01477775 Phase 4 Oral P2Y12 receptor blocker;Customized choice for the oral P2Y12 receptor blocker
50 MICROS-Pilot Study Microcirculation In Acute Coronary Syndromes; Effect of Pre-treatment of High Dose Rosuvastatin on Coronary Microcirculation in Primary PCI Unknown status NCT01382472 Phase 4 Rosuvastatin;Simvastatin

Search NIH Clinical Center for Ischemia

Cochrane evidence based reviews: ischemia

Genetic Tests for Ischemia

Anatomical Context for Ischemia

MalaCards organs/tissues related to Ischemia:

40
Heart, Brain, Liver, Kidney, Endothelial, Testes, Lung

Publications for Ischemia

Articles related to Ischemia:

(show top 50) (show all 51806)
# Title Authors PMID Year
1
Astrocyte targeted overexpression of Hsp72 or SOD2 reduces neuronal vulnerability to forebrain ischemia. 54 61
20235222 2010
2
Ischemia induces endoplasmic reticulum stress and cell apoptosis in human brain. 54 61
20347937 2010
3
Vascular responses to hypoxia and ischemia. 54 61
19729615 2010
4
Protective effect of albumin on VEGF and brain edema in acute ischemia in rats. 54 61
20138968 2010
5
Effects of AMP-activated protein kinase in cerebral ischemia. 54 61
20010958 2010
6
Loss of clusterin expression worsens renal ischemia-reperfusion injury. 54 61
20007348 2010
7
Brief exposure to carbon monoxide preconditions cardiomyogenic cells against apoptosis in ischemia-reperfusion. 54 61
20152804 2010
8
Heme oxygenase-1 protects donor livers from ischemia/reperfusion injury: the role of Kupffer cells. 54 61
20222175 2010
9
Apurinic/apyrimidinic endonuclease APE1 is required for PACAP-induced neuroprotection against global cerebral ischemia. 54 61
20133634 2010
10
A highlight of myoglobin diversity: the nitrite reductase activity during myocardial ischemia-reperfusion. 54 61
19836457 2010
11
Cardiac protection by basic fibroblast growth factor from ischemia/reperfusion-induced injury in diabetic rats. 54 61
20190407 2010
12
Allopurinol, xanthine oxidase, and cardiac ischemia. 54 61
19794315 2009
13
Cardiac macrophage migration inhibitory factor inhibits JNK pathway activation and injury during ischemia/reperfusion. 54 61
19920350 2009
14
Blockade of Hsp20 phosphorylation exacerbates cardiac ischemia/reperfusion injury by suppressed autophagy and increased cell death. 54 61
19850943 2009
15
Role of peroxynitrite and recombinant human manganese superoxide dismutase in reducing ischemia-reperfusion renal tissue injury. 54 61
19917352 2009
16
Low-density lipoproteins oxidized after intestinal ischemia/reperfusion in rats. 54 61
19482302 2009
17
Association of cystatin C with ischemia in patients with coronary heart disease. 54 61
19816865 2009
18
Neuroprotection of ebselen against ischemia/reperfusion injury involves GABA shunt enzymes. 54 61
19576596 2009
19
Ischemia activates the ATF6 branch of the endoplasmic reticulum stress response. 54 61
19622751 2009
20
Involvement of glutamate in retinal protection against ischemia/reperfusion damage induced by post-conditioning. 54 61
19682205 2009
21
Enterocyte shedding and epithelial lining repair following ischemia of the human small intestine attenuate inflammation. 54 61
19753114 2009
22
Lentiviral-mediated overexpression of Bcl-xL protects primary endothelial cells from ischemia/reperfusion injury-induced apoptosis. 54 61
19716047 2009
23
Mesenchymal stem cell-based gene therapy with prostacyclin synthase enhanced neovascularization in hindlimb ischemia. 54 61
19344900 2009
24
Pravastatin accelerates ischemia-induced angiogenesis through AMP-activated protein kinase. 54 61
19498441 2009
25
N-terminal pro-B-type natriuretic peptide and inducible ischemia in the Heart and Soul Study. 54 61
19685518 2009
26
Hypothermia attenuates ischemia/reperfusion-induced endothelial cell apoptosis via alterations in apoptotic pathways and JNK signaling. 54 61
19596001 2009
27
Increased expression of monocarboxylate transporter 1 after acute ischemia of isolated, perfused mouse hearts. 54 61
19604494 2009
28
Use of changes in B-type natriuretic peptides to detect ischemia in selected patients. 54 61
18632168 2009
29
Adrenomedullin ameliorates ischemia reperfusion injury in rat livers. 54 61
19663270 2009
30
The E-selectin ligand basigin/CD147 is responsible for neutrophil recruitment in renal ischemia/reperfusion. 54 61
19443639 2009
31
Dietary sources of nitrite as a modulator of ischemia/reperfusion injury. 54 61
19212422 2009
32
Ischemia/reperfusion Lung Injury Increases Serum Ferritin and Heme Oxygenase-1 in Rats. 54 61
19885035 2009
33
The neuronal apoptotic death in global cerebral ischemia in gerbil: important role for sodium channel modulator. 54 61
19115407 2009
34
Ischemia detected on continuous electrocardiography after acute coronary syndrome: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction 36) trial. 54 61
19371824 2009
35
Angiopoietin-1 in the treatment of ischemia and sepsis. 54 61
18791498 2009
36
Effects of PACAP and preconditioning against ischemia/reperfusion-induced cardiomyocyte apoptosis in vitro. 54 61
19456402 2009
37
Circulating biochemical markers of brain damage in infants complicated by ischemia reperfusion injury. 54 61
19355873 2009
38
Therapeutic benefits of angiogenetic gene-modified human mesenchymal stem cells after cerebral ischemia. 54 61
19094989 2009
39
Transient postprandial ischemia is associated with increased intestinal fatty acid binding protein in patients with chronic gastrointestinal ischemia. 54 61
19279473 2009
40
Neutrophil elastase inhibitor attenuates hippocampal neuronal damage after transient forebrain ischemia in rats. 54 61
19168036 2009
41
FAK regulates cardiomyocyte survival following ischemia/reperfusion. 54 61
19028502 2009
42
Hypertension produced by placental ischemia in pregnant rats is associated with increased soluble endoglin expression. 54 61
19075097 2009
43
[Biochemical markers in the diagnosis of acute coronary syndrome]. 54 61
19681456 2009
44
Central role of Sp1-regulated CD39 in hypoxia/ischemia protection. 54 61
18812468 2009
45
Regulation of cardiac afferent excitability in ischemia. 54 61
19655108 2009
46
Effect of ischemia/reperfusion on bladder nerve and detrusor cell damage. 54 61
18998234 2009
47
Ischemia alters the expression of connexins in the aged human brain. 54 61
19794823 2009
48
Ischemia-induced up-regulation of heme oxygenase-1 protects from apoptotic cell death and tissue necrosis. 54 61
18262556 2008
49
Expression of bystin in reactive astrocytes induced by ischemia/reperfusion and chemical hypoxia in vitro. 54 61
18929647 2008
50
Pretreatment with bone morphogenetic protein-7 (BMP-7) mimics ischemia preconditioning following intestinal ischemia/reperfusion injury in the intestine and liver. 54 61
18461025 2008

Variations for Ischemia

Copy number variations for Ischemia from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 72977 12 89000000 92600000 Copy number GALNT4 Acute coronary syndrome

Expression for Ischemia

Search GEO for disease gene expression data for Ischemia.

Pathways for Ischemia

Pathways related to Ischemia according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.84 VEGFA PRKAA2 NOS3 EPO CASP9 CASP3
2
Show member pathways
12.67 NOS3 EPO EGR1 CXCL12 ADORA3
3 12.64 VEGFA HMOX1 EPO CXCL12 CASP9 CASP3
4
Show member pathways
12.6 NOS3 MAP3K5 EGR1 CASP9 CASP3
5 12.12 NOL3 MAP3K5 CASP9 CASP3
6 11.76 VEGFA REST GJA1 EGR1 CASP3
7 11.74 VEGFA NOS3 HMOX1 EPO
8
Show member pathways
11.69 NOS3 CASP9 CASP3
9 11.67 VEGFA NOS3 EGR1 CASP3
10 11.62 MAP3K5 CASP9 CASP3
11 11.57 NOS3 CASP9 CASP3
12
Show member pathways
11.54 MAP3K5 CXCL12 CASP9 CASP3
13 11.5 VEGFA CASP9 CASP3
14 11.5 VEGFA PRKAA2 NOS3 MAP3K5 HMOX1
15 11.44 VEGFA NOS3 EPO
16 11.38 VEGFA CASP9 CASP3
17 11.37 VEGFA HMOX1 EPO CXCL12
18 11.32 MAP3K5 CASP9 CASP3
19 11.16 NOS3 HMOX1 GJA1
20 11.07 PRKAA2 NOS3 MAP3K5 GJA1 CASP9 CASP3

GO Terms for Ischemia

Biological processes related to Ischemia according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.97 VEGFA PRKAA2 NOL3 HYOU1 EPO CASP3
2 positive regulation of apoptotic process GO:0043065 9.93 REST MAP3K5 HMOX1 CASP9 CASP3
3 regulation of apoptotic process GO:0042981 9.92 NOL3 GJA1 EGR1 CASP9
4 negative regulation of gene expression GO:0010629 9.92 VEGFA REST PRKAA2 ACE
5 apoptotic process GO:0006915 9.87 NOL3 MAP3K5 HMOX1 GJA1 EPO CASP9
6 negative regulation of cell proliferation GO:0008285 9.85 SOD2 REST NOS3 HMOX1 GJA1 ADORA3
7 positive regulation of neuron differentiation GO:0045666 9.8 REST EPO CXCL12
8 response to glucose GO:0009749 9.76 GJA1 EGR1 CASP3
9 regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061418 9.75 VEGFA EPO EGR1
10 response to lipopolysaccharide GO:0032496 9.65 NOS3 GJA1 EPO CASP9 CASP3
11 induction of positive chemotaxis GO:0050930 9.61 VEGFA CXCL12
12 negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway GO:1902176 9.61 SOD2 NOL3
13 blood vessel remodeling GO:0001974 9.61 NOS3 NOL3 ACE
14 removal of superoxide radicals GO:0019430 9.6 SOD2 NOS3
15 positive regulation of chemokine biosynthetic process GO:0045080 9.59 HMOX1 EGR1
16 response to fluid shear stress GO:0034405 9.57 NOS3 GJA1
17 positive regulation of axon extension involved in axon guidance GO:0048842 9.56 VEGFA CXCL12
18 response to cobalt ion GO:0032025 9.55 CASP9 CASP3
19 negative regulation of hypoxia-induced intrinsic apoptotic signaling pathway GO:1903298 9.52 NOL3 HYOU1
20 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.51 VEGFA ACE
21 response to hypoxia GO:0001666 9.5 VEGFA REST HMOX1 EPO EGR1 CXCL12
22 leukocyte apoptotic process GO:0071887 9.48 CASP9 CASP3
23 glial cell apoptotic process GO:0034349 9.46 CASP9 CASP3
24 regulation of blood pressure GO:0008217 9.46 SOD2 NOS3 HMOX1 ACE
25 smooth muscle hyperplasia GO:0014806 9.4 NOS3 HMOX1
26 response to ischemia GO:0002931 9.17 REST NOL3 MAP3K5 HYOU1 GJA1 EGR1

Molecular functions related to Ischemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cysteine-type endopeptidase activity involved in apoptotic process GO:0097153 9.16 CASP9 CASP3
2 death receptor binding GO:0005123 8.96 NOL3 CASP3
3 cysteine-type endopeptidase activity involved in apoptotic signaling pathway GO:0097199 8.62 CASP9 CASP3

Sources for Ischemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....